GSK plc
GLAXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.
Other share classesGSK
- Currency
- GBP
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:30 PM ET
Amounts are in GBP, the currency GSK plc reports in. Lines marked ≈ US$ convert key figures to US dollars.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Revenue | GBP 32.7B≈ US$43.1B | GBP 31.4B≈ US$40.1B | GBP 30.3B≈ US$37.7B | GBP 29.3B≈ US$36.3B | GBP 34.1B≈ US$47.0B |
| Cost of revenue | GBP 9.02B | GBP 9.05B | GBP 8.56B | GBP 9.55B | GBP 11.6B |
| Gross profit | GBP 23.6B | GBP 22.3B | GBP 21.8B | GBP 19.8B | GBP 22.5B |
| Research and development | GBP 7.53B | GBP 6.40B | GBP 6.22B | GBP 5.49B | GBP 5.28B |
| Selling, general and administrative | GBP 9.09B | GBP 11.0B | GBP 9.38B | GBP 8.37B | GBP 11.0B |
| Operating income | GBP 7.93B | GBP 4.02B | GBP 6.75B | GBP 6.43B | GBP 6.20B |
| Interest expense | GBP 701.0M | GBP 669.0M | GBP 792.0M | GBP 879.0M | GBP 784.0M |
| Income tax | GBP 1.11B | GBP 526.0M | GBP 756.0M | GBP 707.0M | GBP 346.0M |
| Net income | GBP 6.29B≈ US$8.30B | GBP 2.95B≈ US$3.77B | GBP 5.31B≈ US$6.60B | GBP 15.6B≈ US$19.3B | GBP 5.10B≈ US$7.01B |
| EPS, basic | GBP 1.41 | GBP 0.632 | GBP 1.22 | GBP 3.71 | GBP 0.876 |
| EPS, diluted | GBP 1.39 | GBP 0.622 | GBP 1.20 | GBP 3.66 | GBP 0.866 |
| Weighted shares, basic | 4.05B | 4.08B | 4.05B | 4.03B | 5.00B |
| Weighted shares, diluted | 4.12B | 4.14B | 4.11B | 4.08B | 5.07B |
| Margins and growth | |||||
| Gross margin | 72.4% | 71.2% | 71.8% | 67.4% | 66.0% |
| Operating margin | 24.3% | 12.8% | 22.2% | 21.9% | 18.2% |
| Net margin | 19.3% | 9.4% | 17.5% | 53.3% | 14.9% |
| Revenue growth, year over year | +4.1% | +3.5% | +3.4% | −14.0% | 0.0% |
| Net income growth, year over year | +113.1% | −44.4% | −66.0% | +206.5% | −20.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Cash and equivalents | GBP 3.40B | GBP 3.87B | GBP 2.94B | GBP 3.72B | GBP 4.27B |
| Accounts receivable | GBP 7.47B | GBP 6.84B | GBP 7.38B | GBP 7.05B | GBP 7.86B |
| Inventory | GBP 5.92B | GBP 5.67B | GBP 5.50B | GBP 5.15B | GBP 5.78B |
| Total current assets | GBP 17.5B | GBP 17.0B | GBP 18.6B | GBP 20.8B | GBP 18.7B |
| Property, plant and equipment | GBP 9.32B | GBP 9.23B | GBP 9.02B | GBP 8.93B | GBP 9.93B |
| Goodwill | GBP 7.02B | GBP 6.98B | GBP 6.81B | GBP 7.05B | GBP 10.6B |
| Intangible assets | GBP 16.7B | GBP 15.5B | GBP 14.8B | GBP 14.3B | GBP 30.1B |
| Total assets | GBP 61.1B≈ US$82.2B | GBP 59.5B≈ US$74.5B | GBP 59.0B≈ US$75.2B | GBP 60.1B≈ US$72.6B | GBP 79.1B≈ US$106.8B |
| Accounts payable | GBP 15.4B | GBP 15.3B | GBP 15.8B | GBP 16.3B | GBP 17.6B |
| Short-term debt | GBP 3.01B | GBP 2.35B | GBP 2.81B | GBP 3.95B | GBP 3.60B |
| Total current liabilities | GBP 21.4B | GBP 21.7B | GBP 21.1B | GBP 22.8B | GBP 23.7B |
| Long-term debt | GBP 14.7B | GBP 14.6B | GBP 15.2B | GBP 17.0B | GBP 20.6B |
| Total liabilities | GBP 45.2B | GBP 46.4B | GBP 46.2B | GBP 50.0B | GBP 57.8B |
| Shareholders' equity | GBP 16.0B | GBP 13.1B | GBP 12.8B | GBP 10.1B | GBP 21.3B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Operating cash flow | GBP 7.74B≈ US$10.2B | GBP 6.55B≈ US$8.38B | GBP 6.77B≈ US$8.42B | GBP 7.40B≈ US$9.16B | GBP 7.95B≈ US$10.9B |
| Capital expenditures | GBP 1.35B | GBP 1.40B | GBP 1.31B | GBP 1.14B | GBP 1.17B |
| Free cash flow | GBP 6.39B≈ US$8.43B | GBP 5.16B≈ US$6.59B | GBP 5.45B≈ US$6.78B | GBP 6.26B≈ US$7.74B | GBP 6.78B≈ US$9.33B |
| Depreciation and amortization | GBP 2.31B | GBP 2.55B | GBP 2.29B | GBP 2.15B | GBP 2.38B |
| Stock-based compensation | GBP 374.0M | GBP 344.0M | GBP 307.0M | GBP 346.0M | GBP 367.0M |
| Share buybacks | GBP 1.38B | – | – | – | – |
| Investing cash flow | GBP -4.23B | GBP -1.23B | GBP -1.59B | GBP -8.77B | GBP -1.78B |
| Financing cash flow | GBP -3.69B | GBP -4.73B | GBP -5.64B | GBP 823.0M | GBP -7.59B |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.1% | 1.1% | 1.0% | 1.2% | 1.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- ≈ US$ figures convert GBP at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.